Clinical Trial Update: A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 ) [Phase 3]

View source ↗

Summary

An extension study (EMPIRE-02) of empagliflozin in patients with refractory diabetes mellitus and insulin resistance is listed as Phase 3, status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insulin Resistance
• Insulin Resistance Syndrome
• Lipoatrophic Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Kobe University | Conditions: Insulin Resistance - Type A, Insulin Resistance - Type B | Phase 3 | Status: UNKNOWN